Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG +2.99%37 EV-to-EBIT is 11.90 as of Sep. 20, 2026, which is 10% above its 10-year median of 10.86. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 5 warning signs investors should review. Among 682 Drug Manufacturers companies, Techno Drugs ranks better than 63.49% on this metric.
The historical rank and industry rank for Techno Drugs's EV-to-EBIT or its related term are showing as below:
DHA:TECHNODRUG'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.45 Med: 10.86 Max: 16.74
Current: 11.94
During the past 3 years, the highest EV-to-EBIT of Techno Drugs was 16.74. The lowest was 8.45. And the median was 10.86.
DHA:TECHNODRUG's EV-to-EBIT is ranked better than 63.49% of 682
companies
in the Drug Manufacturers industry
Industry Median: 16.025
vs DHA:TECHNODRUG: 11.94
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Techno Drugs's Enterprise Value for the quarter that ended in Mar. 2026 was BDT7,439 Mil.
Techno Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT693 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs EV-to-EBIT Related Terms
Techno Drugs EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Techno Drugs's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Techno Drugs's EV-to-EBIT falls into.
Techno Drugs's current Enterprise Value is BDT8,244 Mil.
Techno Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT693 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a EV-to-EBIT of 11.90 as of Sep. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Techno Drugs and its competitors. This is 10% above median its historical median of 10.86. Over the past decade, Techno Drugs' EV-to-EBIT has ranged from 8.45 to 16.74. According to the industry distribution chart, Techno Drugs ranks #249 out of 682 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Techno Drugs' EV-to-EBIT too high?
Techno Drugs' current EV-to-EBIT of 11.90 is 10% above median its 10-year median of 10.86. Over the past 10 years, this metric has ranged from a low of 8.45 to a high of 16.74. The Drug Manufacturers industry median EV-to-EBIT is 16.03. Techno Drugs' value of 11.90 is 25.7% below this industry median. Based on the distribution chart, Techno Drugs ranks #249 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #249 out of 682 companies for EV-to-EBIT. This puts Techno Drugs in the upper half of its industry. The industry median EV-to-EBIT is 16.03. Techno Drugs' value of 11.90 is 25.7% below this benchmark. Historically, Techno Drugs' own EV-to-EBIT has ranged from 8.45 to 16.74 over the past decade. While the company's 10-year median is 10.86 vs. the industry median of 16.03, Techno Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.03, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Techno Drugs's current EV-to-EBIT of 11.90 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current EV-to-EBIT is 11.90, which is 10% above median its own 10-year median of 10.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current EV-to-EBIT of 11.90. The current EV-to-EBIT is 11.90, which is 10% above median its 10-year median of 10.86 and 25.7% below the Drug Manufacturers industry median of 16.03. Techno Drugs' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current EV-to-EBIT is 11.90 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
